{"id":"NCT03875482","sponsor":"AbbVie","briefTitle":"A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-13","primaryCompletion":"2020-02-20","completion":"2020-07-15","firstPosted":"2019-03-14","resultsPosted":"2021-03-16","lastUpdate":"2021-03-16"},"enrollment":157,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Risankizumab","otherNames":["ABBV-066","BI 655066"]},{"type":"DRUG","name":"Placebo solution for risankizumab","otherNames":[]}],"arms":[{"label":"Risankizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16","timeFrame":"At Week 16","effectByArm":[{"arm":"Risankizumab","deltaMin":62.9,"sd":null},{"arm":"Placebo","deltaMin":3.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":43,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["33947295"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":105},"commonTop":[]}}